Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients.

Am J Nephrol

Department of Nephrology and Clinical Transplantation, Medical University, Bialystok, Poland.

Published: February 2007

AI Article Synopsis

  • CC-chemokines play a key role in recruiting immune cells, impacting conditions like atherosclerosis, and the effects of EPO on these factors in hemodialysis (HD) patients are not well understood.
  • A study assessed CC-chemokine levels and intima-media thickness (IMT) in HD patients compared to healthy controls, categorizing patients based on EPO treatment duration and dosage.
  • Results indicated that EPO therapy significantly lowered certain CC-chemokine levels and reduced IMT in HD patients, suggesting prolonged EPO use may benefit cardiovascular health in this population.

Article Abstract

Background: CC-chemokines are now widely accepted in the recruitment of leukocytes from the blood compartment into tissues, and their role in the progression of atherosclerosis has been documented. Recombinant human erythropoietin (EPO) has become widely used to treat anemic HD patients. However, little is known about the effect of EPO on the plasma CC-chemokine levels and intima-media thickness (IMT) in HD patients.

Methods: Assessment of CC-chemokines: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory proteins (MIP-1alpha, MIP-1beta), regulated upon activation, normal T cell expressed and secreted (RANTES) and IMT were performed in 26 stable HD patients and 15 healthy controls. The patients were divided into 3 groups: group I (n = 8, without EPO), group II (n = 9, EPO at a mean dose of 76 +/- 48 U/kg/week for more than 4 months), and group III (n = 9, EPO at a mean dose of 110.5 +/- 21 U/kg/week for more than 12 months), none of them on iron therapy.

Results: MCP-1, MIP-1alpha, MIP-1beta and IMT values were significantly higher, whereas RANTES were significantly lower in HD patients without EPO therapy than those in healthy controls. CC-chemokine levels were found to be significantly lower in patients administered EPO when compared to subjects without EPO. In the patients treated with EPO for more than 12 months IMT values were significantly decreased compared to patients not receiving this hormone.

Conclusion: These results suggest that long-term EPO therapy decreased CC-chemokine and IMT values in patients undergoing regular HD in the absence of concomitant iron supplementation.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000097269DOI Listing

Publication Analysis

Top Keywords

cc-chemokine levels
12
imt values
12
epo
10
patients
9
levels intima-media
8
intima-media thickness
8
patients epo
8
mip-1alpha mip-1beta
8
healthy controls
8
group epo
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!